Pharmacoeconomic and policy

P&P is an open-access, quarterly journal by Xi'an Jiaotong University. We focus on health policy, pharmaco-economics, and innovative medicines

[Pharmacoeconomic and policy @PEP_Journal]

Journal official website:

https://t.co/SlliirqS14

Submission Links:

https://t.co/MOw2slSTtg

E-mail: [email protected]

Tel: [phone]

[Pharmacoeconomic and policy @PEP_Journal]

Is bevifibatide cost-effective for ACS-PCI patients in China? New CEA reports the ICER. https://t.co/ItujcuJvCc #ACS #Cardiology #CEA

[Pharmacoeconomic and policy @PEP_Journal]

Clinical burden & HRQoL in Chinese children with MPS II: new cross-sectional study using PedsQL 4.0. https://t.co/Bmvz2i1Rgt #MPSII #RareDisease #PedsQL

[Pharmacoeconomic and policy @PEP_Journal]

Real-world data reveals treatment patterns in idiopathic pulmonary fibrosis in China — including diagnostic delays and discontinuation. https://t.co/xBrtAichh0 #IPF #RealWorldEvidencev

[Pharmacoeconomic and policy @PEP_Journal]

Toripalimab + bevacizumab vs sorafenib for advanced HCC in China: new cost-effectiveness analysis. https://t.co/6ykhfqdLiA #HCC #Immunotherapy #CEA

[Pharmacoeconomic and policy @PEP_Journal]

Original Article
T2DM burden in the Western Pacific: modeling DALYs and productivity loss from 1990 to 2050 using GBD 2021. https://t.co/LnNrCmuJz5 #T2DM #DiseaseBurden

[Pharmacoeconomic and policy @PEP_Journal]

Review
Systematic review: Is clopidogrel cost-effective for ACS patients undergoing PCI? Evidence and ICERs reviewed. https://t.co/36rwIxnLNu #ACS #PCI #CostEffectiveness

[Pharmacoeconomic and policy @PEP_Journal]

Commentary
The 2025 China Guidelines for Pharmacoeconomic Evaluations are here. Wu & Liu comment on discount rates, WTP thresholds & equity. https://t.co/DsM5o0mAsj #China #Pharmacoeconomics

[Pharmacoeconomic and policy @PEP_Journal]

Original Article
A linked pharmacometrics–pharmacoeconomics model for tacrolimus in liver transplant patients — powered by real-world data. https://t.co/wS0mo8BHux #Pharmacometrics #Pharmacoeconomics #RWD

[Pharmacoeconomic and policy @PEP_Journal]

Antibiotic use in Shanghai, 2017–2024: new longitudinal study uncovers temporal trends and hierarchical disparities across facilities. https://t.co/YasSFmYkai #AntimicrobialResistance #PublicHealth

[Pharmacoeconomic and policy @PEP_Journal]

Original Article
Which fall prevention strategy offers best value for China's older adults? A Markov model CEA compares multiple interventions head-to-head. https://t.co/s7gGq01oXw #FallPrevention #CEA #HealthyAgeing

[Pharmacoeconomic and policy @PEP_Journal]

Original
Are drug promotional materials ethically compliant with WHO criteria? New evidence from an original study—with implications for medicines policy & rational use.
https://t.co/BdplcYjA0d

#DrugPromotion #WHO

[Pharmacoeconomic and policy @PEP_Journal]

What's driving the disease burden of pulmonary arterial hypertension? GBD 2021 data reveals the top three attributable risk factors. https://t.co/d6SCHW73xy

#PAH #DiseaseBurden #GBD2021

[Pharmacoeconomic and policy @PEP_Journal]

Can traditional Chinese medicine products be evaluated with CEA and QALYs? New review maps the progress, challenges & methodological suggestions. https://t.co/9qLzRDe00l #ChineseMedicine #Pharmacoeconomics

[Pharmacoeconomic and policy @PEP_Journal]

Review:
Can traditional Chinese medicine products be evaluated with CEA and QALYs? New review maps the progress, challenges & methodological suggestions.
https://t.co/9qLzRDe00l
#ChineseMedicine #Pharmacoeconomics #P&P

[Pharmacoeconomic and policy @PEP_Journal]

Review:
How do leading HTA agencies around the world differ — and what can others learn? A comparative review of assessment methodology, decision influence & capacity building.
https://t.co/CZKh4LOHX5
#HTA #HealthPolicy #P&P

[Pharmacoeconomic and policy @PEP_Journal]

Perspective:
Regional RWE requirements are reshaping pharma strategy in East Asia. How can the industry prepare for Conditional Reimbursement List frameworks? A new Perspective explains. https://t.co/fnLEPf4XkO
#RWE #HTA #Pharmacoeconomics

[Pharmacoeconomic and policy @PEP_Journal]

Call for Papers

Reform of Traditional Chinese Medicine Health System: Integration, Payment, Evaluation & Digital Innovation Deadline: 31 Jan 2027
Topics: TCM hospitals, insurance, DRG/DIP, digital health, AI & more
Submit: https://t.co/gU1jLMNOqB

#TCM #CallForPapers

[Pharmacoeconomic and policy @PEP_Journal]

Call for Papers: Reform of TCM Health System – Integration, Payment, Evaluation & Digital Innovation. Deadline: 31 Jan 2027. Submit your research!
https://t.co/gU1jLMOmg9

[Pharmacoeconomic and policy @PEP_Journal]

Despite declining age-standardized prevalence rates, PAH burden remains a major concern. Joinpoint and decomposition analyses reveal trends and the impact of three key factors from 1990–2021. Find more:
https://t.co/d6SCHW7Bn6
#PAH #PulmonaryHypertension #GlobalBurdenOfDisease

[Pharmacoeconomic and policy @PEP_Journal]

New comparative review of 10 HTA agencies worldwide! How do governance, structure & policy integration shape HTA impact?
link: https://t.co/Ola0kRlY0p #HealthTechnologyAssessment